Recent publications demonstrating the clinical utility of the CMV assay represent a step toward diversifying into different types of assays, the firm said.
As a result of its collaboration with Quest Diagnostics, Oxford Immunotec is experiencing a surge in orders from physician offices for its interferon gamma release assay TB kits.
The firm is investing in commercial resources and research and development to capitalize on continued expansion in the global tuberculosis market, according to its CEO.
The firm said that it ended a distributor agreement that it had inked in 2013 with Fosun Long March Medical Science and Shanghai Xin Chang Medical Device.
UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening.
